ERBB2 L755P

CI-VAR-00002413Explore in graph →NP_004439.2:p.Leu755ProNM_004448.3:c.2263_2264delinsCCClinVar 13877 CIViC 1304 rs121913469

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma3
ERBB2 L755P	Osimertinib	Predictive	C	Supports Sensitivity Response	1	submitted	EID12107 Osimertinib was effective in achieving a partial response in a patient with stage IV non-small cell lung cancer metastasis in the brain harboring ERBB2 exon 19 c.2262_2264delinsTCC, p.(L755P) variant.… (full text at CIViC) PMID 37197637 · Jonsdottir et al., 2023 · Open in CIViC	civic
ERBB2 L755P	Trastuzumab Deruxtecan	Predictive	A	Supports Sensitivity Response	2	accepted	EID11754 In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13877	Pathogenic/Likely pathogenic	no assertion criteria provided	0	Lung adenocarcinoma	somatic	2	Sep 30, 2004	clinvar

Malignant Neoplasm1
ERBB2 L755P	Lapatinib	Predictive	D	Supports Resistance	2	accepted	EID3005 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-L755P showed IC50 value of 1545nM, and was considered as lapatinib-resistant. PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic